Zhenoluten

Zhenoluten is a peptide complex bioregulator classified as a Cytomax for ovarian tissue in the Khavinson system. It is manufactured by extraction from ovarian tissue of young calves under 12 months old using the patented Khavinson process. Constituent peptides have molecular weights up to approximately 10 kDa.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts containing heterogeneous mixtures of peptides. Cytogens are short synthetic peptides designed to reproduce single defined active sequences. For female reproductive tissue, Zhenoluten is the Cytomax. A widely marketed defined-sequence ovarian Cytogen counterpart is not part of the standard Khavinson product line, distinguishing this organ system from those with both Cytomax and Cytogen products (testes: Testoluten Cytomax and Testagen Cytogen; pineal: Endoluten Cytomax and Epitalon Cytogen).

The compound is described across Khavinson group publications on peptide bioregulation. The mechanistic framework (nuclear peptide-DNA interaction modulating tissue-specific gene expression) is applied to Zhenoluten as it is to other Cytomaxes, though the specific constituent peptides responsible for ovarian-tissue effects have not been individually characterized in the way that thymic peptides have been.

The Evidence

The compound-specific evidence base consists of:

• Russian-institution observational studies in menopausal women and women with age-related reproductive function decline
• Reports of subjective improvement in menopausal symptom scores after 30-day courses
• Use in adjunct protocols for premature ovarian insufficiency and irregular menstrual cycles in younger women
• Inclusion in broader Khavinson geroprotective protocols for women
• Animal data on ovarian morphology preservation in aging models

Independent Western confirmation is absent. PubMed indexing returns no English-language randomized controlled trials specifically for Zhenoluten. No registered ClinicalTrials.gov study exists.

The compound's claims overlap with substantial evidence-based pharmaceutical alternatives. Hormone replacement therapy (estrogen, with progesterone in women with intact uteri) has decades of Phase 3 trial evidence for menopausal symptom management. The Women's Health Initiative and subsequent reanalyses have clarified the risk-benefit profile for HRT use across different age groups and risk categories. Non-hormonal pharmaceutical alternatives include SSRIs and SNRIs for hot flashes, fezolinetant for vasomotor symptoms, and various agents for specific menopausal concerns. Zhenoluten sits outside this evidence-based clinical framework.

Regulatory and Legal Status

FDA. No approval. Not on bulk drug substances list.

EMA. No approval.

Russia. Registered as a biologically active dietary supplement.

WADA. Not on 2026 Prohibited List.

The proposed mechanism follows the Khavinson short-peptide bioregulation model with ovarian-tissue specificity.

Cellular entry and DNA interaction. Short peptides from the Zhenoluten complex are hypothesized to enter ovarian granulosa cells, theca cells, and other ovarian cell types, reach the nucleus, and modulate gene expression. The Khavinson model treats this as the basis for tissue-selective effects.

Proposed downstream effects. Khavinson group publications describe ovarian peptide complex effects on:

• Granulosa cell function and survival
• Modulation of steroidogenic enzyme expression
• Effects on folliculogenesis markers in animal models
• Possible effects on age-related ovarian follicle depletion patterns
• Modulation of inflammatory and stress-response markers in ovarian tissue

Specific gene-expression changes have not been mapped in independent transcriptomic studies. Tissue-specificity claims rest on functional observations in animal models and on the broader Khavinson framework.

Comparison with established mechanisms. Pharmaceutical approaches to menopausal symptoms and reproductive support work through well-characterized mechanisms. Exogenous estrogen directly engages estrogen receptors. Selective estrogen receptor modulators (SERMs) provide tissue-selective effects through receptor modulation. Fezolinetant blocks neurokinin B receptors in the hypothalamus to reduce vasomotor symptoms. The Khavinson proposed mechanism (ovarian gene-expression modulation by short peptides) is not a class targeted by any approved pharmaceutical.

Pharmacokinetics. Bovine-origin peptide complexes face the same challenge as any orally administered peptide: gut hydrolysis to free amino acids. The Khavinson framework proposes signaling at the gut-mucosa interface propagated systemically. Direct measurement of plasma peptide levels after Zhenoluten administration is not published.

Human pharmacokinetic data is not published.

Russian-institution observational data and manufacturer documentation report:

• Subjective improvement in menopausal symptom scores (hot flashes, mood, sleep quality)
• Modest improvements in subjective quality of life in women during perimenopause and menopause
• Possible effects on menstrual cycle regularity in younger women with cycle irregularities
• Adjunct use in protocols for ovarian function support in women with premature ovarian insufficiency
• Inclusion in geroprotective protocols for women

Effect magnitudes reported are substantially smaller than those produced by hormone replacement therapy. The non-blinded observational study designs preclude rigorous evaluation of efficacy versus placebo response.

Research-chemical user reports outside Russia are uncommon for Zhenoluten compared with other Khavinson Cytomaxes. The female-specific positioning limits the broader research-chemical community interest.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Zhenoluten.

The Russian retail product is dosed as 1 to 2 capsules once or twice daily during meals for a 30-day course, repeated 2 to 3 times per year. Each capsule contains approximately 10 mg of active ovarian peptide complex.

The course-and-cycle pattern is standard Khavinson protocol. Optimal cycle spacing for Zhenoluten has not been independently validated.

Subcutaneous research-chemical use is uncommon for Cytomaxes. Injection of bovine-derived heterogeneous peptide mixtures carries higher infectious and immunogenicity risk than injection of single defined synthetic peptides.

The Khavinson bioregulator class has a benign published adverse-event profile. Russian manufacturer documentation for Zhenoluten lists individual intolerance, pregnancy, lactation, and age below 14 years as contraindications.

The animal-tissue origin creates a distinct safety profile compared with synthetic Cytogens. Theoretical concerns specific to Zhenoluten include:

• Contamination risk from bovine source tissue
• Theoretical prion-related concerns from bovine-derived products
• Potential immunogenicity from foreign-protein exposure
• Endotoxin risk in any injectable forms

Long-term human safety data with controlled endpoints does not exist.

Theoretical concerns specific to chronic use in female populations:

• Effects on patients with active or prior hormone-sensitive cancers (breast, endometrial, ovarian) have not been evaluated
• Effects on patients on hormonal contraceptives or hormone replacement therapy have not been studied
• Drug-drug interactions with selective estrogen receptor modulators, aromatase inhibitors, and other reproductive endocrine medications are uncharacterized
• Effects on bone density in long-term use have not been formally evaluated (a relevant question for any compound used during the menopausal transition where bone loss accelerates)

For women with diagnosed gynecologic disease, hormone-sensitive cancer history, or other significant medical complexity, the relevant safety consideration is not Zhenoluten's direct toxicity but the risk of substituting unproven supplements for evidence-based care.

Within the Khavinson system, Zhenoluten is the female reproductive Cytomax. A widely marketed synthetic Cytogen counterpart specifically for ovarian tissue is not part of the standard product line.

For broader urogenital and reproductive coverage in female protocols, Zhenoluten combines with:

• Vesilute (bladder Cytogen for urogenital support)
• Ovagen (liver/GI Cytogen for hormonal metabolism support)
• Glandokort (adrenal Cytomax for HPA-axis coverage)
• Epitalon (pineal Cytogen for circadian and broader aging support)

The Khavinson female reproductive protocol typically pairs Zhenoluten with other organ-specific bioregulators in comprehensive geroprotective regimens. No combined-stack human trial has been published.

External evidence-based comparators for menopausal symptoms and female reproductive function have substantial Phase 3 trial data:

• Estrogen and combined HRT for vasomotor and genitourinary symptoms (decades of trial data, well-characterized risk-benefit)
• SSRIs and SNRIs (paroxetine FDA-approved for vasomotor symptoms; venlafaxine, escitalopram, sertraline off-label evidence)
• Fezolinetant (NK3 receptor antagonist, FDA-approved 2023 for moderate-to-severe vasomotor symptoms)
• Vaginal estrogen for genitourinary syndrome of menopause
• Bisphosphonates and other agents for postmenopausal bone health

Zhenoluten has no comparable evidence base for any specific menopausal or reproductive indication and is not a substitute for evidence-based care in symptomatic women.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.